

Francesc Bosch

List of Publications by Citations

Source: <https://exaly.com/author-pdf/2031739/francesc-bosch-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

219
papers

9,032
citations

44
h-index

93
g-index

229
ext. papers

10,068
ext. citations

4.5
avg, IF

5.19
L-index

| # | Paper | IF | Citations |
|-----|--|------|-----------|
| 219 | ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. <i>New England Journal of Medicine</i> , 2003 , 348, 1764-75 | 59.2 | 1093 |
| 218 | The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. <i>Cancer Cell</i> , 2003 , 3, 185-97 | 24.3 | 751 |
| 217 | Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: Pathogenetic implications and clinical correlations. <i>Blood</i> , 2007 , 109, 259-70 | 2.2 | 402 |
| 216 | Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. <i>Cancer Research</i> , 2010 , 70, 1408-18 | 10.1 | 373 |
| 215 | Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. <i>Nature Medicine</i> , 2012 , 18, 221-3 | 50.5 | 363 |
| 214 | Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. <i>Blood</i> , 2003 , 101, 78-84 | 2.2 | 322 |
| 213 | Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. <i>Archives of Internal Medicine</i> , 1998 , 158, 1889-93 | | 273 |
| 212 | Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors. <i>Cancer</i> , 1998 , 82, 567-75 | 6.4 | 254 |
| 211 | Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification. <i>Annals of Oncology</i> , 1998 , 9, 849-55 | 10.3 | 227 |
| 210 | Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin. <i>Journal of Clinical Oncology</i> , 2005 , 23, 2797-804 | 2.2 | 205 |
| 209 | Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival. <i>Blood</i> , 2007 , 109, 4599-606 | 2.2 | 183 |
| 208 | Nucleotide sequence, transcription map, and mutation analysis of the 13q14 chromosomal region deleted in B-cell chronic lymphocytic leukemia. <i>Blood</i> , 2001 , 97, 2098-104 | 2.2 | 165 |
| 207 | Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2002 , 119, 976-84 | 4.5 | 146 |
| 206 | A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study. <i>Leukemia</i> , 2016 , 30, 929-36 | 10.7 | 142 |
| 205 | NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome. <i>Leukemia</i> , 2013 , 27, 1100-6 | 10.7 | 135 |
| 204 | ATM gene inactivation in mantle cell lymphoma mainly occurs by truncating mutations and missense mutations involving the phosphatidylinositol-3 kinase domain and is associated with increasing numbers of chromosomal imbalances. <i>Blood</i> , 2002 , 99, 238-44 | 2.2 | 132 |
| 203 | Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia ("accelerated" chronic lymphocytic leukemia) with aggressive clinical behavior. <i>Haematologica</i> , 2010 , 95, 1526-33 | 6.6 | 126 |

| | | | |
|-----|---|------|-----|
| 202 | Improving survival in patients with chronic lymphocytic leukemia (1980-2008): the Hospital Clinic of Barcelona experience. <i>Blood</i> , 2009 , 114, 2044-50 | 2.2 | 120 |
| 201 | Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia. <i>Journal of Clinical Oncology</i> , 2005 , 23, 3433-8 | 2.2 | 116 |
| 200 | Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia. <i>Blood</i> , 2006 , 107, 4563-9 | 2.2 | 114 |
| 199 | Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia. <i>Journal of Clinical Oncology</i> , 2009 , 27, 4578-84 | 2.2 | 111 |
| 198 | Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines. <i>Blood</i> , 2019 , 134, 6-6 | 2.2 | 105 |
| 197 | Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication. <i>Clinical Cancer Research</i> , 2008 , 14, 155-61 | 12.9 | 103 |
| 196 | Spontaneous and drug-induced apoptosis is mediated by conformational changes of Bax and Bak in B-cell chronic lymphocytic leukemia. <i>Blood</i> , 2002 , 100, 1810-6 | 2.2 | 102 |
| 195 | Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study. <i>Lancet Haematology</i> , 2019 , 6, e67-e78 | 14.6 | 95 |
| 194 | The Follicular Lymphoma International Prognostic Index (FLIPI) and the histological subtype are the most important factors to predict histological transformation in follicular lymphoma. <i>Annals of Oncology</i> , 2006 , 17, 1539-45 | 10.3 | 93 |
| 193 | Increased expression of the PRAD-1/CCND1 gene in hairy cell leukaemia. <i>British Journal of Haematology</i> , 1995 , 91, 1025-30 | 4.5 | 88 |
| 192 | Nuclear survivin expression in mantle cell lymphoma is associated with cell proliferation and survival. <i>American Journal of Pathology</i> , 2004 , 164, 501-10 | 5.8 | 86 |
| 191 | Chronic lymphocytic leukaemia: from genetics to treatment. <i>Nature Reviews Clinical Oncology</i> , 2019 , 16, 684-701 | 19.4 | 85 |
| 190 | Five-gene model to predict survival in mantle-cell lymphoma using frozen or formalin-fixed, paraffin-embedded tissue. <i>Journal of Clinical Oncology</i> , 2008 , 26, 4966-72 | 2.2 | 82 |
| 189 | CDK4 and MDM2 gene alterations mainly occur in highly proliferative and aggressive mantle cell lymphomas with wild-type INK4a/ARF locus. <i>Cancer Research</i> , 2005 , 65, 2199-206 | 10.1 | 80 |
| 188 | Central nervous system involvement in mantle cell lymphoma. <i>Annals of Oncology</i> , 2008 , 19, 135-41 | 10.3 | 79 |
| 187 | How I treat refractory CLL. <i>Blood</i> , 2006 , 107, 1276-83 | 2.2 | 76 |
| 186 | Genetic imbalances in progressed B-cell chronic lymphocytic leukemia and transformed large-cell lymphoma (Richter's syndrome). <i>American Journal of Pathology</i> , 2002 , 161, 957-68 | 5.8 | 75 |
| 185 | Leukemic involvement is a common feature in mantle cell lymphoma. <i>Cancer</i> , 2007 , 109, 2473-80 | 6.4 | 69 |

| | | | |
|-----|--|------|----|
| 184 | Residual splenic function after laparoscopic splenectomy: a clinical concern. <i>Archives of Surgery</i> , 1998 , 133, 56-60 | | 67 |
| 183 | Genetic variants in apoptosis and immunoregulation-related genes are associated with risk of chronic lymphocytic leukemia. <i>Cancer Research</i> , 2008 , 68, 10178-86 | 10.1 | 64 |
| 182 | Immunohistochemical analysis of ZAP-70 expression in B-cell lymphoid neoplasms. <i>Journal of Pathology</i> , 2005 , 205, 507-13 | 9.4 | 62 |
| 181 | Prognostic significance of the loss of heterozygosity of Nm23-H1 and p53 genes in human colorectal carcinomas. <i>Cancer</i> , 1994 , 73, 2913-21 | 6.4 | 61 |
| 180 | Predictive value of Follicular Lymphoma International Prognostic Index (FLIPI) in patients with follicular lymphoma at first progression. <i>Annals of Oncology</i> , 2004 , 15, 1484-9 | 10.3 | 59 |
| 179 | Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2012 , 53, 417-23 | 1.9 | 51 |
| 178 | Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia. <i>Blood</i> , 2013 , 122, 3951-9 | 2.2 | 47 |
| 177 | Impact of response to treatment on survival in multiple myeloma: results in a series of 243 patients. <i>British Journal of Haematology</i> , 1994 , 88, 117-21 | 4.5 | 47 |
| 176 | ZAP-70 enhances migration of malignant B lymphocytes toward CCL21 by inducing CCR7 expression via IgM-ERK1/2 activation. <i>Blood</i> , 2011 , 118, 4401-10 | 2.2 | 45 |
| 175 | Abdominal computed tomography predicts progression in patients with Rai stage 0 chronic lymphocytic leukemia. <i>Journal of Clinical Oncology</i> , 2007 , 25, 1576-80 | 2.2 | 43 |
| 174 | ZAP-70 expression in normal pro/pre B cells, mature B cells, and in B-cell acute lymphoblastic leukemia. <i>Clinical Cancer Research</i> , 2006 , 12, 726-34 | 12.9 | 40 |
| 173 | Expression of potentially oncogenic HHV-8 genes in an EBV-negative primary effusion lymphoma occurring in an HIV-seronegative patient. <i>Journal of Pathology</i> , 1999 , 189, 288-93 | 9.4 | 40 |
| 172 | Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice. <i>British Journal of Haematology</i> , 2018 , 180, 666-679 | 4.5 | 38 |
| 171 | Patients with chronic lymphocytic leukemia and complex karyotype show an adverse outcome even in absence of deletions. <i>Oncotarget</i> , 2017 , 8, 54297-54303 | 3.3 | 37 |
| 170 | Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. <i>Lancet Haematology</i> , 2017 , 4, e475-e486 | 14.6 | 36 |
| 169 | Donor lymphocyte infusions in AML and MDS: Enhancing the graft-versus-leukemia effect. <i>Experimental Hematology</i> , 2017 , 48, 1-11 | 3.1 | 35 |
| 168 | Combination of the Hematopoietic Cell Transplantation Comorbidity Index and the European Group for Blood and Marrow Transplantation score allows a better stratification of high-risk patients undergoing reduced-toxicity allogeneic hematopoietic cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 66-72 | 4.7 | 34 |
| 167 | Survival after progression in patients with follicular lymphoma: analysis of prognostic factors. <i>Annals of Oncology</i> , 2002 , 13, 523-30 | 10.3 | 34 |

| | | | |
|-----|--|------|----|
| 166 | Follicular lymphoma in early stages: high risk of relapse and usefulness of the Follicular Lymphoma International Prognostic Index to predict the outcome of patients. <i>European Journal of Haematology</i> , 2006 , 76, 58-63 | 3.8 | 33 |
| 165 | Incidence and clinical significance of bcl-2/IgH rearrangements in follicular lymphoma. <i>Leukemia and Lymphoma</i> , 2003 , 44, 71-6 | 1.9 | 33 |
| 164 | Expression of beta-integrin adhesion molecules in non-Hodgkin's lymphoma: correlation with clinical and evolutive features. <i>Journal of Clinical Oncology</i> , 1999 , 17, 1869-75 | 2.2 | 33 |
| 163 | Co-culture of primary CLL cells with bone marrow mesenchymal cells, CD40 ligand and CpG ODN promotes proliferation of chemoresistant CLL cells phenotypically comparable to those proliferating in vivo. <i>Oncotarget</i> , 2015 , 6, 7632-43 | 3.3 | 33 |
| 162 | Pyoderma gangrenosum triggered by alpha2b-interferon in a patient with chronic granulocytic leukemia. <i>Leukemia and Lymphoma</i> , 1998 , 30, 199-202 | 1.9 | 32 |
| 161 | Clinico-biological characterization and outcome of primary nodal and extranodal diffuse large B-cell lymphoma in the rituximab era. <i>Leukemia and Lymphoma</i> , 2010 , 51, 1225-32 | 1.9 | 31 |
| 160 | Bone marrow assessment in B-cell chronic lymphocytic leukaemia: aspirate or biopsy? A comparative study in 258 patients. <i>British Journal of Haematology</i> , 1996 , 93, 111-6 | 4.5 | 30 |
| 159 | Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Preliminary Activity in Acute Leukemia of Ory-1001, a First-in-Class Inhibitor of Lysine-Specific Histone Demethylase 1A (LSD1/KDM1A): Initial Results from a First-in-Human Phase 1 Study. <i>Blood</i> , 2016 , 128, 4060-4060 | 2.2 | 29 |
| 158 | Lack of methylthioadenosine phosphorylase expression in mantle cell lymphoma is associated with shorter survival: implications for a potential targeted therapy. <i>Clinical Cancer Research</i> , 2006 , 12, 3754-61 | 12.9 | 28 |
| 157 | Simultaneous diagnosis of hairy cell leukemia and chronic lymphocytic leukemia/small lymphocytic lymphoma: a frequent association?. <i>Leukemia</i> , 2002 , 16, 1454-9 | 10.7 | 28 |
| 156 | Translocation (11;14)(q13;q32) and preferential involvement of chromosomes 1, 2, 9, 13, and 17 in mantle cell lymphoma. <i>Cancer Genetics and Cytogenetics</i> , 1999 , 111, 92-8 | | 28 |
| 155 | Cutaneous lymphocyte-associated antigen (CLA) expression in a lymphoblastoid mantle cell lymphoma presenting with skin lesions. Comparison with other clinicopathologic presentations of mantle cell lymphoma. <i>Journal of Cutaneous Pathology</i> , 2001 , 28, 256-64 | 1.7 | 26 |
| 154 | Cell free circulating tumor DNA in cerebrospinal fluid detects and monitors central nervous system involvement of B-cell lymphomas. <i>Haematologica</i> , 2021 , 106, 513-521 | 6.6 | 25 |
| 153 | Autoimmune disorders are common in myelodysplastic syndrome patients and confer an adverse impact on outcomes. <i>Annals of Hematology</i> , 2018 , 97, 1349-1356 | 3 | 24 |
| 152 | A Low Frequency of Losses in 11q Chromosome Is Associated with Better Outcome and Lower Rate of Genomic Mutations in Patients with Chronic Lymphocytic Leukemia. <i>PLoS ONE</i> , 2015 , 10, e0143073 | 3.7 | 23 |
| 151 | Karyotypic complexity rather than chromosome 8 abnormalities aggravates the outcome of chronic lymphocytic leukemia patients with TP53 aberrations. <i>Oncotarget</i> , 2016 , 7, 80916-80924 | 3.3 | 23 |
| 150 | Clinical implications of ZAP-70 expression in chronic lymphocytic leukemia. <i>Cytometry Part B - Clinical Cytometry</i> , 2006 , 70, 214-7 | 3.4 | 22 |
| 149 | Activation of mitochondrial apoptotic pathway in mantle cell lymphoma: high sensitivity to mitoxantrone in cases with functional DNA-damage response genes. <i>Oncogene</i> , 2004 , 23, 8941-9 | 9.2 | 22 |

| | | | |
|-----|---|------|----|
| 148 | Prognostic features and outcome in patients with diffuse large B-cell lymphoma who do not achieve a complete response to first-line regimens. <i>Cancer</i> , 2001 , 91, 1557-1562 | 6.4 | 22 |
| 147 | Selection and viral load kinetics of an oseltamivir-resistant pandemic influenza A (H1N1) virus in an immunocompromised patient during treatment with neuraminidase inhibitors. <i>Diagnostic Microbiology and Infectious Disease</i> , 2010 , 68, 214-9 | 2.9 | 21 |
| 146 | A high proportion of cells carrying trisomy 12 is associated with a worse outcome in patients with chronic lymphocytic leukemia. <i>Hematological Oncology</i> , 2016 , 34, 84-92 | 1.3 | 21 |
| 145 | Clinical outcome and prognostic factors of patients with Richter syndrome: real-world study of the Spanish Chronic Lymphocytic Leukemia Study Group (GELLC). <i>British Journal of Haematology</i> , 2020 , 190, 854-863 | 4.5 | 20 |
| 144 | Obinutuzumab plus bendamustine in previously untreated patients with CLL: a subgroup analysis of the GREEN study. <i>Leukemia</i> , 2018 , 32, 1778-1786 | 10.7 | 20 |
| 143 | Induction of histone H1.2 cytosolic release in chronic lymphocytic leukemia cells after genotoxic and non-genotoxic treatment. <i>Haematologica</i> , 2008 , 93, 75-82 | 6.6 | 20 |
| 142 | Updated Survival Analysis from the CLL11 Study: Obinutuzumab Versus Rituximab in Chemoimmunotherapy-Treated Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015 , 126, 1733-1733 | 2.2 | 20 |
| 141 | An assessment of the clinicohematological criteria for the accelerated phase of chronic myeloid leukemia. <i>European Journal of Haematology</i> , 1996 , 57, 286-91 | 3.8 | 19 |
| 140 | First-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4260-4273 | 2.2 | 19 |
| 139 | Gene expression profiling in chronic lymphocytic leukaemia. <i>Best Practice and Research in Clinical Haematology</i> , 2009 , 22, 211-22 | 4.2 | 18 |
| 138 | Hematopoietic stem cell transplantation in chronic lymphocytic leukemia: a report of 12 patients from a single institution. <i>Annals of Oncology</i> , 1998 , 9, 167-72 | 10.3 | 18 |
| 137 | Targeting the proliferative and chemoresistant compartment in chronic lymphocytic leukemia by inhibiting survivin protein. <i>Leukemia</i> , 2014 , 28, 1993-2004 | 10.7 | 17 |
| 136 | Microenvironment regulates the expression of miR-21 and tumor suppressor genes PTEN, PIAS3 and PDCD4 through ZAP-70 in chronic lymphocytic leukemia. <i>Scientific Reports</i> , 2017 , 7, 12262 | 4.9 | 16 |
| 135 | Low-grade lymphoma: clinical and prognostic studies in a series of 143 patients from a single institution. <i>Leukemia and Lymphoma</i> , 1994 , 15, 159-65 | 1.9 | 15 |
| 134 | Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study.. <i>Journal of Clinical Oncology</i> , 2021 , JCO2100931 | 2.3 | 15 |
| 133 | Restricted T cell receptor repertoire in CLL-like monoclonal B cell lymphocytosis and early stage CLL. <i>OncImmunology</i> , 2018 , 7, e1432328 | 7.2 | 14 |
| 132 | Aminoglycoside-associated severe renal failure in patients with multiple myeloma treated with thalidomide. <i>Leukemia and Lymphoma</i> , 2004 , 45, 1711-2 | 1.9 | 14 |
| 131 | Malignant transformation in IgM monoclonal gammopathy of undetermined significance. <i>Seminars in Oncology</i> , 2003 , 30, 178-81 | 5.5 | 14 |

| | | | |
|-----|---|------|----|
| 130 | Facing real-life with direct oral anticoagulants in patients with nonvalvular atrial fibrillation: outcomes from the first observational and prospective study in a Spanish population. <i>Journal of Comparative Effectiveness Research</i> , 2019 , 8, 165-178 | 2.1 | 13 |
| 129 | Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the phase IIIb GREEN study. <i>Haematologica</i> , 2018 , 103, 1889-1898 | 6.6 | 13 |
| 128 | Salvage chemotherapy with alternating MINE-ESHAP regimen in relapsed or refractory Hodgkin's lymphoma followed by autologous stem-cell transplantation. <i>Annals of Oncology</i> , 2010 , 21, 1211-1216 | 10.3 | 13 |
| 127 | Inhibition of BCR signaling using the Syk inhibitor TAK-659 prevents stroma-mediated signaling in chronic lymphocytic leukemia cells. <i>Oncotarget</i> , 2017 , 8, 742-756 | 3.3 | 13 |
| 126 | Promising activity of selinexor in the treatment of a patient with refractory diffuse large B-cell lymphoma and central nervous system involvement. <i>Haematologica</i> , 2018 , 103, e92-e93 | 6.6 | 12 |
| 125 | Analysis of the IGHV region in Burkitt's lymphomas supports a germinal center origin and a role for superantigens in lymphomagenesis. <i>Leukemia Research</i> , 2014 , 38, 509-15 | 2.7 | 12 |
| 124 | Biallelic losses of 13q do not confer a poorer outcome in chronic lymphocytic leukaemia: analysis of 627 patients with isolated 13q deletion. <i>British Journal of Haematology</i> , 2013 , 163, 47-54 | 4.5 | 11 |
| 123 | ZAP-70 promotes the infiltration of malignant B-lymphocytes into the bone marrow by enhancing signaling and migration after CXCR4 stimulation. <i>PLoS ONE</i> , 2013 , 8, e81221 | 3.7 | 11 |
| 122 | Gene expression profile and genomic changes in disease progression of early-stage chronic lymphocytic leukemia. <i>Haematologica</i> , 2008 , 93, 132-6 | 6.6 | 11 |
| 121 | True anti-anionic phospholipid immunoglobulin M antibodies can exert lupus anticoagulant activity. <i>British Journal of Haematology</i> , 2002 , 116, 875-86 | 4.5 | 11 |
| 120 | Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced hodgkin disease 2000 , 88, 2142-2148 | | 11 |
| 119 | Safety and Efficacy of Obinutuzumab Plus Bendamustine in Previously Untreated Patients with Chronic Lymphocytic Leukemia: Subgroup Analysis of the Green Study. <i>Blood</i> , 2015 , 126, 493-493 | 2.2 | 11 |
| 118 | Pathological assessment of gastrointestinal biopsies from patients with idelalisib-associated diarrhea and colitis. <i>Future Oncology</i> , 2018 , 14, 2265-2277 | 3.6 | 10 |
| 117 | Risk of relapse and clinico-pathological features in 103 patients with diffuse large-cell lymphoma in complete response after first-line treatment. <i>European Journal of Haematology</i> , 1998 , 61, 59-64 | 3.8 | 10 |
| 116 | Lenalidomide Maintenance after Front Line Therapy Substantially Prolongs Progression Free Survival in High Risk CLL: Interim Results of a Phase 3 Study (CLL M1 study of the German CLL Study Group). <i>Blood</i> , 2016 , 128, 229-229 | 2.2 | 10 |
| 115 | Posttransplant cyclophosphamide after allogeneic hematopoietic cell transplantation mitigates the immune activation induced by previous nivolumab therapy. <i>Leukemia</i> , 2020 , 34, 3420-3425 | 10.7 | 9 |
| 114 | Limitations of Gallium-67 SPECT in histological transformation of chronic lymphocytic leukaemia: an analysis of 13 patients with clinically suspected Richter's syndrome. <i>British Journal of Haematology</i> , 2002 , 119, 484-7 | 4.5 | 9 |
| 113 | Repurposing dasatinib for diffuse large B cell lymphoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019 , 116, 16981-16986 | 11.5 | 8 |

| | | | |
|-----|--|------|---|
| 112 | Refining prognostic factors in chronic lymphocytic leukemia. <i>Reviews in Clinical and Experimental Hematology</i> , 2002 , 6, 335-49; discussion 449-50 | | 8 |
| 111 | Preliminary Safety Results from the Phase IIIb GREEN Study of Obinutuzumab (GA101) Alone or in Combination with Chemotherapy for Previously Untreated or Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2014 , 124, 3345-3345 | 2.2 | 8 |
| 110 | Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies. <i>Blood Advances</i> , 2021 , | 7.8 | 8 |
| 109 | Clinical characteristics and outcome of SARS-CoV-2 infection in admitted patients with chronic lymphocytic leukemia from a single European country. <i>Experimental Hematology and Oncology</i> , 2020 , 9, 37 | 7.8 | 7 |
| 108 | A Systematic Review and Network Meta-Analysis to Evaluate the Comparative Efficacy of Interventions for Unfit Patients with Chronic Lymphocytic Leukemia. <i>Advances in Therapy</i> , 2016 , 33, 1814-1830 | 4.7 | 7 |
| 107 | Personalizing treatment for chronic lymphocytic leukemia. <i>Expert Review of Hematology</i> , 2011 , 4, 27-35 | 2.8 | 7 |
| 106 | Updated Results from a Phase 1 Study of TAK-659, an Investigational and Reversible SYK Inhibitor, in Patients (Pts) with Advanced Solid Tumor or Lymphoma Malignancies. <i>Blood</i> , 2016 , 128, 624-624 | 2.2 | 7 |
| 105 | Characterizing patients with multiple chromosomal aberrations detected by FISH in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2018 , 59, 633-642 | 1.9 | 6 |
| 104 | Interleukin 6 and tumour necrosis factor alpha serum levels in monoclonal gammopathy of undetermined significance. <i>British Journal of Haematology</i> , 2002 , 117, 387-9 | 4.5 | 6 |
| 103 | Mitoxantrone and intermediate-dose cytosine arabinoside for poor-risk acute leukemias: response to treatment and factors influencing outcome. <i>Hematological Oncology</i> , 1992 , 10, 301-9 | 1.3 | 6 |
| 102 | Beyond hemostasis: the challenge of treating plasminogen deficiency. A report of three cases. <i>Journal of Thrombosis and Thrombolysis</i> , 2016 , 41, 544-7 | 5.1 | 5 |
| 101 | Prognosis Assessment of Early-Stage Chronic Lymphocytic Leukemia: Are We Ready to Predict Clinical Evolution Without a Crystal Ball?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020 , 20, 548-555.e4 | 2.4 | 5 |
| 100 | Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-Cell Lymphoma. <i>Clinical Cancer Research</i> , 2020 , 26, 3546-3556 | 12.9 | 4 |
| 99 | Venetoclax after idelalisib: relevant progress for CLL. <i>Blood</i> , 2018 , 131, 1632-1633 | 2.2 | 4 |
| 98 | Posttransplant monomorphic Burkitt's lymphoma: clinical characteristics and outcome of a multicenter series. <i>Annals of Hematology</i> , 2018 , 97, 2417-2424 | 3 | 4 |
| 97 | Differential gene expression profile associated to apoptosis induced by dexamethasone in CLL cells according to IGHV/ZAP-70 status. <i>Clinical Cancer Research</i> , 2012 , 18, 5924-33 | 12.9 | 4 |
| 96 | ZAP-70 in chronic lymphocytic leukemia. <i>New England Journal of Medicine</i> , 2003 , 349, 506-7; author reply 506-7 | 59.2 | 4 |
| 95 | Study of Causes of Death in Patients with Myelodysplastic Syndrome: A Single Institution Experience. <i>Blood</i> , 2011 , 118, 5026-5026 | 2.2 | 4 |

| | | | |
|----|---|------|---|
| 94 | Pathology Results of Tissue Biopsy during Idelalisib-Associated Diarrhea/Colitis. <i>Blood</i> , 2016 , 128, 4391-4391 | 4.3 | 4 |
| 93 | Repolarization of tumor infiltrating macrophages and increased survival in mouse primary CNS lymphomas after XPO1 and BTK inhibition. <i>Journal of Neuro-Oncology</i> , 2020 , 149, 13-25 | 4.8 | 4 |
| 92 | Chromosome banding analysis and genomic microarrays are both useful but not equivalent methods for genomic complexity risk stratification in chronic lymphocytic leukemia patients. <i>Haematologica</i> , 2021 , | 6.6 | 4 |
| 91 | Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study. <i>Leukemia</i> , 2020 , 34, 441-450 | 10.7 | 4 |
| 90 | Polycythaemia vera following non-Hodgkin's lymphoma. <i>Leukemia and Lymphoma</i> , 1992 , 8, 501-2 | 1.9 | 3 |
| 89 | Clinical Characteristics and Outcome of a Large Series of Patients with Chronic Lymphocytic Leukemia (CLL) According to ZAP-70 Expression.. <i>Blood</i> , 2004 , 104, 14-14 | 2.2 | 3 |
| 88 | XPO1 Inhibition By Selinexor Synergizes with BCR Inhibition, Blocks Tumor Growth and Prolongs Survival in a Bioluminescent Animal Model of Primary Central Nervous System Lymphoma. <i>Blood</i> , 2016 , 128, 463-463 | 2.2 | 3 |
| 87 | Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients. <i>Leukemia and Lymphoma</i> , 2021 , 1-13 | 1.9 | 3 |
| 86 | Donor lymphocyte infusion for BK virus hemorrhagic cystitis and nephropathy: a case report. <i>Bone Marrow Transplantation</i> , 2019 , 54, 772-774 | 4.4 | 3 |
| 85 | Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study. <i>British Journal of Haematology</i> , 2021 , 193, 325-338 | 4.5 | 3 |
| 84 | Antitumor Activity of the Novel BTK Inhibitor TG-1701 Is Associated with Disruption of Ikaros Signaling in Patients with B-cell Non-Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2021 , 27, 6591-6601 | 12.9 | 3 |
| 83 | Ibrutinib in CLL: 2 sides of the same coin. <i>Blood</i> , 2015 , 126, 2173-4 | 2.2 | 2 |
| 82 | Primary gastrointestinal aspergillosis 6 months after allogeneic hematopoietic cell transplantation: a case report. <i>Transplant Infectious Disease</i> , 2013 , 15, E107-10 | 2.7 | 2 |
| 81 | Worldwide Examination of Patients with CLL Hospitalized for COVID-19. <i>Blood</i> , 2020 , 136, 45-49 | 2.2 | 2 |
| 80 | An Individualized Risk Mitigation Approach for Safety: Experience from the Mosunetuzumab (CD20/CD3 Bispecific Antibody) Development Program in Relation to Neurotoxicity Risk. <i>Blood</i> , 2019 , 134, 4728-4728 | 2.2 | 2 |
| 79 | Computed Tomography (CT) Predicts Response Duration in Patients with Chronic Lymphocytic Leukemia (CLL) in Complete Response (CR) by Conventional, NCI-Working Group, Criteria.. <i>Blood</i> , 2006 , 108, 2835-2835 | 2.2 | 2 |
| 78 | Rituximab Plus Gemcitabine and Oxaliplatin as Salvage Therapy In Patients with Relapsed/Refractory Mantle-Cell Lymphoma.. <i>Blood</i> , 2010 , 116, 2825-2825 | 2.2 | 2 |
| 77 | Good Tolerance of Lenalidomide Maintenance Therapy in Patients with High Risk Profile Chronic Lymphocytic Leukemia (CLL) after Frontline Chemoimmunotherapy: Preliminary Safety Overview of the CLLM1 Trial of the German CLL Study Group (GCLLSG). <i>Blood</i> , 2014 , 124, 4699-4699 | 2.2 | 2 |

| | | | |
|----|--|-----|---|
| 76 | Chronic lymphocytic leukemia-like monoclonal B-cell lymphocytosis exhibits an increased inflammatory signature that is reduced in early-stage chronic lymphocytic leukemia. <i>Experimental Hematology</i> , 2021 , 95, 68-80 | 3.1 | 2 |
| 75 | Immunological and genetic kinetics from diagnosis to clinical progression in chronic lymphocytic leukemia. <i>Biomarker Research</i> , 2021 , 9, 37 | 8 | 2 |
| 74 | Prognostic impact of total metabolic tumor volume in large B-cell lymphoma patients receiving CAR T-cell therapy. <i>Annals of Hematology</i> , 2021 , 100, 2303-2310 | 3 | 2 |
| 73 | Dichotomization of the new revised international prognostic scoring system for a better clinical stratification of patients with myelodysplastic syndromes. <i>Leukemia and Lymphoma</i> , 2019 , 60, 1522-1527 ¹⁻⁹ | | 2 |
| 72 | Reduced expansion of CD94/NKG2C NK cells in chronic lymphocytic leukemia and CLL-like monoclonal B-cell lymphocytosis is not related to increased human cytomegalovirus seronegativity or NKG2C deletions. <i>International Journal of Laboratory Hematology</i> , 2021 , 43, 1032-1040 | 2.5 | 2 |
| 71 | Update of the Grupo Español de Leucemia Linfocítica Crónica clinical guidelines of the management of chronic lymphocytic leukemia. <i>Medicina Clínica</i> , 2017 , 148, 381.e1-381.e9 | 1 | 1 |
| 70 | Graft-Versus-Host Disease (GVHD) Prophylaxis with Post-Transplant Cyclophosphamide (PTCY) Induces a More Tolerant Immune Response after Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) in Patients Previously Exposed to Nivolumab. <i>Blood</i> , 2018 , 132, 3402-3402 | 2.2 | 1 |
| 69 | Obinutuzumab Alone or Combined with Chemotherapy in Previously Untreated (Fit or Unfit) or Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Patients: Final Results from the Phase IIIb GREEN Safety Study with a Focus on Efficacy. <i>Blood</i> , 2019 , 134, 3035-3035 | 2.2 | 1 |
| 68 | Over 20% of Patients with Chronic Lymphocytic Leukemia Carry Stereotyped Receptors: Pathogenetic Implications and Clinical Correlations.. <i>Blood</i> , 2006 , 108, 26-26 | 2.2 | 1 |
| 67 | FMNL-1 (Formin-Like 1) Gene in Chronic Lymphocytic Leukemia (CLL) Is Overexpressed in Young Patients with Adverse Prognostic Factors and Poor Outcome.. <i>Blood</i> , 2006 , 108, 2775-2775 | 2.2 | 1 |
| 66 | Changes in the Natural History, Treatment Modalities, and Survival Patterns in Patients with Chronic Lymphocytic Leukemia (CLL) from 1980 to 2008. The Hospital Clinic of Barcelona Experience. <i>Blood</i> , 2008 , 112, 48-48 | 2.2 | 1 |
| 65 | Final Results of the Phase I Study of Lenalidomide In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL-001 Study). <i>Blood</i> , 2010 , 116, 1376-1376 | 2.2 | 1 |
| 64 | Rituximab Maintenance In Patients with Chronic Lymphocytic Leukemia (CLL) After Upfront Treatment with Rituximab Plus Fludarabine, Cyclophosphamide, and Mitoxantrone (R-FCM): Final Results of a Multicenter Phase II Trial On Behalf of the Spanish CLL Study Group (GELLC). <i>Blood</i> , 2011 , 118, 293-293 | 2.2 | 1 |
| 63 | Rituximab Plus Gemcitabine and Oxaliplatin As Salvage Therapy in Patients with Relapsed/Refractory Mantle-Cell Lymphoma. <i>Blood</i> , 2012 , 120, 1627-1627 | 2.2 | 1 |
| 62 | Lenalidomide and Dexamethasone Combination in Patients with Chronic Lymphocytic Leukemia (CLL) Relapsing or Resistant to Treatment (LENDEX-LLC-09): A Gene Expression Profiling Study. <i>Blood</i> , 2014 , 124, 4675-4675 | 2.2 | 1 |
| 61 | Acute Ischemic Events in Patient Receiving Direct Oral Anticoagulants for Atrial Fibrillation: Incidence, Outcome and Clinical Profile. <i>Blood</i> , 2016 , 128, 1442-1442 | 2.2 | 1 |
| 60 | Polatuzumab Vedotin Combined with Bendamustine (B) and Rituximab (R) or Obinutuzumab (G) in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of a Phase Ib/II Dose-Escalation Study. <i>Blood</i> , 2016 , 128, 4194-4194 | 2.2 | 1 |
| 59 | Prognostic Indicators of Chronic Lymphocytic Leukemia 2004 , 201-215 | | 1 |

| | | | |
|----|---|-----|---|
| 58 | Effect of syk inhibition by TAK659 on proliferative, survival, and migratory signals from the microenvironment in chronic lymphocytic leukemia.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 7058-7058 | 2.2 | 1 |
| 57 | Are Direct Oral Anticoagulants Plasma Concentrations Associated with the Risk of Postoperative Bleeding? Results from the Real Life Cohort. <i>Blood</i> , 2016 , 128, 3819-3819 | 2.2 | 1 |
| 56 | Feasibility of thiotepa addition to the fludarabine-busulfan conditioning with tacrolimus/sirolimus as graft vs host disease prophylaxis. <i>Leukemia and Lymphoma</i> , 2020 , 61, 1823-1832 | 1.9 | 1 |
| 55 | Acquired von Willebrand syndrome in a patient with small lymphocytic lymphoma and Sjgren's syndrome: which associated condition should be prioritized?. <i>Blood Coagulation and Fibrinolysis</i> , 2019 , 30, 239-242 | 1 | 1 |
| 54 | Analysis of Cell Subsets in Donor Lymphocyte Infusions from HLA Identical Sibling Donors after Allogeneic Hematopoietic Cell Transplant. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 53.e1-53.e8 | | 1 |
| 53 | Combination of novel molecular targeted agent plus R-CHOP-based regimen versus R-CHOP alone in previously untreated diffuse large B-cell lymphoma (DLBCL) patients: a systematic review and meta-analysis. <i>Annals of Hematology</i> , 2021 , 100, 2969-2978 | 3 | 1 |
| 52 | Building a network of TP53 and IGHV testing reference centers across Spain: the Red53 initiative. <i>Annals of Hematology</i> , 2021 , 100, 825-830 | 3 | 1 |
| 51 | Constitutive Activation of p62/Sequestosome-1-Mediated Proteophagy Regulates Proteolysis and Impairs Cell Death in Bortezomib-Resistant Mantle Cell Lymphoma.. <i>Cancers</i> , 2022 , 14, | 6.6 | 1 |
| 50 | Neurotoxicity-associated sinus bradycardia after chimeric antigen receptor T-cell therapy.. <i>Hematological Oncology</i> , 2022 , | 1.3 | 0 |
| 49 | Early Relapse after First Line Has a Significant Impact on Overall Survival in Patients with Mantle Cell Lymphoma (MCL). <i>Blood</i> , 2021 , 138, 1357-1357 | 2.2 | 0 |
| 48 | Preliminary Results of Ibrutinib Followed By Ofatumumab Consolidation in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): GELLC7 Trials from the Spanish Group of CLL (GELLC). <i>Blood</i> , 2019 , 134, 4296-4296 | 2.2 | 0 |
| 47 | Is acute lymphoblastic leukemia with mature B-cell phenotype and rearrangements a new entity? A systematic review and meta-analysis. <i>Leukemia and Lymphoma</i> , 2021 , 62, 2202-2210 | 1.9 | 0 |
| 46 | Selection process and causes of non-eligibility for CD19 CAR-T cell therapy in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma in a European center. <i>Leukemia and Lymphoma</i> , 2021 , 62, 2288-2291 | 1.9 | 0 |
| 45 | Interleukin-1 receptor associated kinase 1/4 and bromodomain and extra-terminal inhibitions converge on NF- κ B blockade and display synergistic antitumoral activity in activated B-cell subset of diffuse large B-cell lymphoma with L265P mutation. <i>Haematologica</i> , 2021 , 106, 2749-2753 | 6.6 | 0 |
| 44 | 5.40 Rituximab Maintenance in Patients with Chronic Lymphocytic Leukemia after First-Line Treatment with Rituximab plus Fludarabine, Cyclophosphamide, and Mitoxantrone: Final Results of a Multicenter Phase II Trial on Behalf of the Spanish CLL Study Group (GELLC). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011 , 11, S270-S272 | 2 | |
| 43 | The IV International Chronic Lymphocytic Leukemia Young Investigators' Meeting. <i>Leukemia and Lymphoma</i> , 2010 , 51, 1369-1370 | 1.9 | |
| 42 | Prognostic Impact of Metabolic Tumor Burden in Large B-Cell Lymphoma Patients Receiving CAR T-Cell Therapy. <i>Blood</i> , 2020 , 136, 27-29 | 2.2 | |
| 41 | Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Hematologic Patients: Experience at the Hospital Attending More Patients in Spain. <i>Blood</i> , 2020 , 136, 30-31 | 2.2 | |

| | | |
|----|--|-----|
| 40 | Real-World Data with the Use of Caplacizumab in the Treatment of Acquired Thrombotic Thrombocytopenic Purpura (aTTP). <i>Blood</i> , 2020 , 136, 14-16 | 2.2 |
| 39 | Excellent Clinical and Pharmacokinetic Real-World Experience after Switching to Rurioctocog ALFA Pegol. <i>Blood</i> , 2020 , 136, 26-27 | 2.2 |
| 38 | Variant t(11;22)(q13;q11.2) with involvement in mantle cell lymphoma.. <i>Leukemia and Lymphoma</i> , 2022 , 1-4 | 1.9 |
| 37 | Epidemiological Characterization and Determination of TP53 and IGHV Mutational Status of a Large Series of Previously-Untreated Chronic Lymphocytic Leukemia (CLL) Patients in Spain: The Epicll Study. <i>Blood</i> , 2021 , 138, 1564-1564 | 2.2 |
| 36 | High Cyclin D1 Expression Is Associated with Increased Proliferation Rate and Decreased Survival in Mantle Cell Lymphoma (MCL) and Is Caused by Genomic Deletions and Mutations that Enhance Stability of Cyclin D1 mRNA.. <i>Blood</i> , 2004 , 104, 697-697 | 2.2 |
| 35 | Quantitative PCR Predicts Early Relapse in Patients with Chronic Lymphocytic Leukemia (CLL) Submitted to Autologous Stem Cell Transplantation. The Case for Early Clinical Intervention.. <i>Blood</i> , 2004 , 104, 2255-2255 | 2.2 |
| 34 | Expression of Specialized Error-Prone DNA Polymerases in Chronic Lymphocytic Leukemia (CLL).. <i>Blood</i> , 2005 , 106, 2941-2941 | 2.2 |
| 33 | High Expression of Human Leukocyte Formin Protein in T Non-Hodgkin's Lymphomas and in CD19 ⁺ Cell Population of Normal Tonsils.. <i>Blood</i> , 2005 , 106, 4662-4662 | 2.2 |
| 32 | Dexamethasone Induces Apoptosis <i>In Vivo</i> in Chronic Lymphocytic Leukemia Cells with Either Unmutated IgVH Genes or High ZAP-70 Expression.. <i>Blood</i> , 2005 , 106, 2945-2945 | 2.2 |
| 31 | Cytosolic Histone H1.2 Releasing under Different Apoptotic Stimuli in Chronic Lymphocytic Leukemia (CLL).. <i>Blood</i> , 2005 , 106, 2108-2108 | 2.2 |
| 30 | Clinical Significance of Minimal Residual Disease (MRD), as Assessed by Different Techniques, after Stem Cell Transplantation (SCT) for Chronic Lymphocytic Leukemia (CLL).. <i>Blood</i> , 2005 , 106, 2018-2018 | 2.2 |
| 29 | ZAP-70 Expression and Stem Cell Transplantation Results in Patients with CLL.. <i>Blood</i> , 2006 , 108, 3670-3670 | 2.2 |
| 28 | Primary Extranodal Follicular Lymphoma: Clinicobiological Features and Outcome.. <i>Blood</i> , 2006 , 108, 2456-2456 | 2.2 |
| 27 | Histone H1.2 Releasing under Different Apoptotic Stimuli in Chronic Lymphocytic Leukemia (CLL).. <i>Blood</i> , 2007 , 110, 1141-1141 | 2.2 |
| 26 | SNP Array Analysis Reveals Copy Number Alterations and Uniparental Disomy in Mantle Cell Lymphomas at High Resolution.. <i>Blood</i> , 2007 , 110, 1585-1585 | 2.2 |
| 25 | Chronic Lymphocytic Leukemia (CLL): A Comparative Analysis of Protein Expression Profiles in Peripheral Blood Cells at Diagnosis and upon Disease Progression.. <i>Blood</i> , 2007 , 110, 1129-1129 | 2.2 |
| 24 | Preliminary Results of the Combination Rituximab, Fludarabine, Cyclophosphamide and Mitoxantrone (R-FCM) Followed by Rituximab Maintenance in Previously Untreated Chronic Lymphocytic Leukemia (CLL).. <i>Blood</i> , 2007 , 110, 626-626 | 2.2 |
| 23 | B-cell acute lymphoblastic leukemia (B-ALL) in CLL patients treated with lenalidomide.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 7531-7531 | 2.2 |

| | | |
|----|---|-----|
| 22 | Early Normalization of Serum Free Light Chain (FLC) Assays Correlates with Profound and Prolonged Responses in Newly Diagnosed Multiple Myeloma (MM). <i>Blood</i> , 2018 , 132, 1897-1897 | 2.2 |
| 21 | A Complementary Role of High Throughput Sequencing and Multiparameter Cytometry for Minimal Residual Disease (MRD) Detection in Chronic Lymphocytic Leukemia (CLL):an European Research Initiative (ERIC) Study. <i>Blood</i> , 2014 , 124, 1976-1976 | 2.2 |
| 20 | Microna Mir-21 Is Upregulated after Different Microenvironmental Stimuli and Controls Proliferation, Chemotaxis and Chemoresistance in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2014 , 124, 1971-1971 | 2.2 |
| 19 | Syk Inhibition By TAK-659 Overcomes Proliferative, Survival and Migratory Signals from the Microenvironment in Chronic Lymphocytic Leukemia Cells. <i>Blood</i> , 2014 , 124, 4698-4698 | 2.2 |
| 18 | Ocular Adnexal Marginal Zone Lymphomas (OAMZL): Lack of Evidence for Chlamydia Psittaci (C. Psittaci) Infection in a Clinicopathologic Study from a Single Institution. <i>Blood</i> , 2014 , 124, 4467-4467 | 2.2 |
| 17 | A Spin-Off in Non Valvular Atrial Fibrillation (NVAf) and Cancer : Doacs As a Safe and Effective Alternative to the Convencional Avks. <i>Blood</i> , 2016 , 128, 5021-5021 | 2.2 |
| 16 | Assessment of Measures to Reduce Infusion-Related Reactions in Patients with Chronic Lymphocytic Leukemia Treated with Obinutuzumab in the GREEN Study. <i>Blood</i> , 2016 , 128, 5589-5589 | 2.2 |
| 15 | No Benefit from Rituximab Containing Regimens in Patients with Primary Extranodal Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2008 , 112, 3615-3615 | 2.2 |
| 14 | Chronic Lymphocytic Leukemia Apoptotic Cell Death Induced by Glucocorticoids Is Mediated by BIM and GILZ and Can Be Predicted by FKBP5 Basal Expression Levels.. <i>Blood</i> , 2009 , 114, 1236-1236 | 2.2 |
| 13 | The Prognostic Significance of Autoimmune Cytopenias in Patients with Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2009 , 114, 2361-2361 | 2.2 |
| 12 | Immune Status In Patients with Chronic Lymphocytic Leukemia and Sustained Complete Remission: A Multiparametric Analysis. <i>Blood</i> , 2010 , 116, 1389-1389 | 2.2 |
| 11 | Applicability of Different Immunohistochemistry Algorithms to Assess Gene Expression Profile In Patients with Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2010 , 116, 4134-4134 | 2.2 |
| 10 | ZAP-70 Enhances BCR Signaling and Migration of Malignant B Lymphocytes towards CCL21 Via Induction of CCR7 Expression. <i>Blood</i> , 2010 , 116, 3591-3591 | 2.2 |
| 9 | ZAP-70 Enhances Migration of Malignant B Cells towards Lymphoid Organs in a Burkitt Lymphoma Xenograft Model. <i>Blood</i> , 2011 , 118, 2844-2844 | 2.2 |
| 8 | Differential Expression of Adhesion Molecules and Chemokine Receptors Confers Increased Migrative Capacity to ZAP-70-Positive Subclones in CLL Primary Cells,. <i>Blood</i> , 2011 , 118, 3889-3889 | 2.2 |
| 7 | YM155, a Small-Molecule Survivin Suppressant, Mainly Targets Primary CLL Cells Actively Proliferating and Overcomes Microenvironment-Mediated CLL Cell Protection. <i>Blood</i> , 2012 , 120, 3868-3868 | 2.2 |
| 6 | ZAP-70 Enhances Infiltration of Malignant B Lymphocytes Into the Bone Marrow by Increasing Migratory and Survival Responses to CXCR4 Stimulation. <i>Blood</i> , 2012 , 120, 1779-1779 | 2.2 |
| 5 | Prognostic Impact of the MRD Status After Induction Treatment with Rituximab Plus Fludarabine, Cyclophosphamide and Mitoxantrone (R-FCM) in Patients with Chronic Lymphocytic Leukemia Receiving Rituximab Maintenance Therapy. <i>Blood</i> , 2012 , 120, 3930-3930 | 2.2 |

- 4 Intensive Immunochemotherapy In Patients With B-Cell Lymphoma, Unclassifiable (B-UCL), With Features Intermediate Between Diffuse Large B-Cell Lymphoma (DLBCL) and Burkitt Lymphoma (BL): A Comparison With BL Patients Treated With The Same Protocol In The Pethema-Burkimab-04 Trial. *Blood*, **2013**, 122, 1793-1793 2.2
- 3 Venetoclax-obinutuzumab: harnessing complexity. *Blood*, **2020**, 135, 788-789 2.2
- 2 Genetics of Chronic Lymphocytic Leukemia. *Cancer Journal (Sudbury, Mass)*, **2021**, 27, 259-265 2.2
- 1 Improving treatment approach in patients with chronic lymphocytic leukemia. *Psychophysiology*, **2005**, 4, 243-4